Clinical Trial Update: Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating human IL-15 and obinutuzumab in relapsed/refractory chronic lymphocytic leukemia was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• rhIL-15 (human interleukin-15) (interleukin-15)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphocytic | Phase 1 | Status: TERMINATED | Results posted: 2022-03-10